|
1
|
Cantile M, Schiavo G, Terracciano L and
Cillo C: Homeobox genes in normal and abnormal vasculogenesis. Nutr
Metab Cardiovasc Dis. 18:651–658. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hayashida T, Takahashi F, Chiba N,
Brachtel E, Takahashi M, Godin-Heymann N, Gross KW, Vivanco M,
Wijendran V, Shioda T, et al: HOXB9, a gene overexpressed in
breast cancer, promotes tumorigenicity and lung metastasis. Proc
Natl Acad Sci USA. 107:1100–1105. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chiba N, Comaills V, Shiotani B, Takahashi
F, Shimada T, Tajima K, Winokur D, Hayashida T, Willers H, Brachtel
E, et al: Homeobox B9 induces epithelial-to-mesenchymal
transition-associated radioresistance by accelerating DNA damage
responses. Proc Natl Acad Sci USA. 109:2760–2765. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sherman M: Hepatocellular carcinoma:
Epidemiology, surveillance, and diagnosis. Semin Liver Dis.
30:3–16. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rampone B, Schiavone B, Martino A, Viviano
C and Confuorto G: Current management strategy of hepatocellular
carcinoma. World J Gastroenterol. 15:3210–3216. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: SHARP Investigators Study Group: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al:
BAY 43–9006 exhibits broad spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ha TU, Segev DL, Barbie D, Masiakos PT,
Tran TT, Dombkowski D, Glander M, Clarke TR, Lorenzo HK, Donahoe
PK, et al: Mullerian inhibiting substance inhibits ovarian cell
growth through an Rb-independent mechanism. J Biol Chem.
275:37101–37109. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Seki H, Hayashida T, Jinno H, Hirose S,
Sakata M, Takahashi M, Maheswaran S, Mukai M and Kitagawa Y: HOXB9
expression promoting tumor cell proliferation and angiogenesis is
associated with clinical outcomes in breast cancer patients. Ann
Surg Oncol. 19:1831–1840. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hoshino Y, Hayashida T, Hirata A,
Takahashi H, Chiba N, Ohmura M, Wakui M, Jinno H, Hasegawa H,
Maheswaran S, et al: Bevacizumab terminates homeobox B9-induced
tumor proliferation by silencing microenvironmental communication.
Mol Cancer. 13:102–108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu L, Cao Y, Chen C, Zhang X, McNabola A,
Wilkie D, Wilhelm S, Lynch M and Carter C: Sorafenib blocks the
RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor
cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer
Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Abate-Shen C: Deregulated homeobox gene
expression in cancer: Cause or consequence? Nat Rev Cancer.
2:777–785. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jain RK: Molecular regulation of vessel
maturation. Nat Med. 9:685–693. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shrestha B, Ansari KI, Bhan A, Kasiri S,
Hussain I and Mandal SS: Homeodomain-containing protein HOXB9
regulates expression of growth and angiogenic factors, facilitates
tumor growth in vitro and is overexpressed in breast cancer tissue.
FEBS J. 279:3715–3726. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nguyen DX, Chiang AC, Zhang XH, Kim JY,
Kris MG, Ladanyi M, Gerald WL and Massagué J: WNT/TCF signaling
through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.
Cell. 138:51–62. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Abou-Alfa GK, Schwartz L, Ricci S, Amadori
D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz
B, et al: Phase II study of sorafenib in patients with advanced
hepatocellular carcinoma. J Clin Oncol. 24:4293–4300. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Newell P, Toffanin S, Villanueva A, Chiang
DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH,
Melgar-Lesmes P, et al: Ras pathway activation in hepatocellular
carcinoma and anti-tumoral effect of combined sorafenib and
rapamycin in vivo. J Hepatol. 51:725–733. 2009. View Article : Google Scholar : PubMed/NCBI
|
